(DVA) DaVita HealthCare Partners - Ratings and Ratios
Kidney Dialysis, Lab Services, Hemodialysis, Clinical Laboratories, Kidney Care
DVA EPS (Earnings per Share)
DVA Revenue
Description: DVA DaVita HealthCare Partners
DaVita Inc. is a leading provider of kidney dialysis services in the United States, operating numerous outpatient dialysis centers and offering a range of related services, including lab testing, disease management, and physician services. The companys comprehensive kidney care services cater to patients with chronic kidney failure, providing them with various treatment options, including hemodialysis and transplant software solutions.
From a financial perspective, DaVitas revenue growth is largely driven by the number of patients it serves, as well as the average revenue per patient. Key performance indicators (KPIs) to watch include the companys patient count, revenue per treatment, and operating margins. With a strong presence in the US healthcare market, DaVitas competitive positioning is influenced by factors such as its network of dialysis centers, quality of care, and ability to negotiate favorable contracts with payers.
In terms of valuation, DaVitas price-to-earnings (P/E) ratio of 14.14 suggests a relatively reasonable valuation compared to its earnings. Additionally, the companys return on equity (RoE) of 393.58 indicates a high level of profitability, suggesting that DaVita is generating significant earnings relative to its equity base. Other relevant KPIs include the companys debt-to-equity ratio, interest coverage, and cash flow generation, which can provide further insights into its financial health and stability.
To further analyze DaVitas prospects, it is essential to examine industry trends, such as the growing prevalence of chronic kidney disease, the shift towards value-based care, and the competitive landscape. By understanding these factors, investors can better assess DaVitas potential for long-term growth and profitability. Key metrics to monitor include the companys same-center growth, patient satisfaction scores, and its ability to expand its integrated care offerings.
DVA Stock Overview
| Market Cap in USD | 9,850m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 1995-10-31 |
DVA Stock Ratings
| Growth Rating | 2.12% |
| Fundamental | 74.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -33.7% |
| Analyst Rating | 3.10 of 5 |
DVA Dividends
Currently no dividends paidDVA Growth Ratios
| Growth Correlation 3m | -56.9% |
| Growth Correlation 12m | -80% |
| Growth Correlation 5y | 49.6% |
| CAGR 5y | 12.61% |
| CAGR/Max DD 3y | 0.36 |
| CAGR/Mean DD 3y | 1.46 |
| Sharpe Ratio 12m | 0.55 |
| Alpha | 0.11 |
| Beta | 0.761 |
| Volatility | 31.15% |
| Current Volume | 737.1k |
| Average Volume 20d | 692.2k |
| Stop Loss | 126.2 (-3%) |
| Signal | -0.70 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (836.3m TTM) > 0 and > 6% of Revenue (6% = 789.7m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -0.10pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 8.77% (prev 3.77%; Δ 5.00pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 1.86b > Net Income 836.3m (YES >=105%, WARN >=100%) |
| Net Debt (12.11b) to EBITDA (2.71b) ratio: 4.47 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (77.4m) change vs 12m ago -13.03% (target <= -2.0% for YES) |
| Gross Margin 32.54% (prev 31.16%; Δ 1.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 76.26% (prev 73.56%; Δ 2.69pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.60 (EBITDA TTM 2.71b / Interest Expense TTM 554.4m) >= 6 (WARN >= 3) |
Altman Z'' 1.68
| (A) 0.07 = (Total Current Assets 4.09b - Total Current Liabilities 2.93b) / Total Assets 17.49b |
| (B) 0.11 = Retained Earnings (Balance) 1.90b / Total Assets 17.49b |
| (C) 0.12 = EBIT TTM 2.00b / Avg Total Assets 17.26b |
| (D) 0.11 = Book Value of Equity 1.76b / Total Liabilities 15.94b |
| Total Rating: 1.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 74.94
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 6.51% = 3.25 |
| 3. FCF Margin 9.79% = 2.45 |
| 4. Debt/Equity 88.26 = -2.50 |
| 5. Debt/Ebitda 3.95 = -2.50 |
| 6. ROIC - WACC (= 11.98)% = 12.50 |
| 7. RoE data missing |
| 8. Rev. Trend 93.33% = 7.00 |
| 9. EPS Trend 74.68% = 3.73 |
What is the price of DVA shares?
Over the past week, the price has changed by -4.83%, over one month by -2.36%, over three months by -5.61% and over the past year by -21.24%.
Is DaVita HealthCare Partners a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DVA is around 116.60 USD . This means that DVA is currently overvalued and has a potential downside of -10.38%.
Is DVA a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 8
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the DVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 153.5 | 18% |
| Analysts Target Price | 153.5 | 18% |
| ValueRay Target Price | 125.7 | -3.4% |
Last update: 2025-09-03 04:36
DVA Fundamental Data Overview
CCE Cash And Equivalents = 739.4m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 13.5724
P/E Forward = 12.6422
P/S = 0.7484
P/B = 21.6266
P/EG = 1.8072
Beta = 1.088
Revenue TTM = 13.16b USD
EBIT TTM = 2.00b USD
EBITDA TTM = 2.71b USD
Long Term Debt = 10.08b USD (from longTermDebt, last quarter)
Short Term Debt = 611.7m USD (from shortTermDebt, last quarter)
Debt = 10.69b USD (Calculated: Short Term 611.7m + Long Term 10.08b)
Net Debt = 12.11b USD (from netDebt column, last quarter)
Enterprise Value = 19.80b USD (9.85b + Debt 10.69b - CCE 739.4m)
Interest Coverage Ratio = 3.60 (Ebit TTM 2.00b / Interest Expense TTM 554.4m)
FCF Yield = 6.51% (FCF TTM 1.29b / Enterprise Value 19.80b)
FCF Margin = 9.79% (FCF TTM 1.29b / Revenue TTM 13.16b)
Net Margin = 6.35% (Net Income TTM 836.3m / Revenue TTM 13.16b)
Gross Margin = 32.54% ((Revenue TTM 13.16b - Cost of Revenue TTM 8.88b) / Revenue TTM)
Tobins Q-Ratio = 11.26 (Enterprise Value 19.80b / Book Value Of Equity 1.76b)
Interest Expense / Debt = 1.37% (Interest Expense 146.1m / Debt 10.69b)
Taxrate = 18.27% (279.7m / 1.53b)
NOPAT = 1.63b (EBIT 2.00b * (1 - 18.27%))
Current Ratio = 1.39 (Total Current Assets 4.09b / Total Current Liabilities 2.93b)
Debt / Equity = 88.26 (Debt 10.69b / last Fiscal Year total Stockholder Equity 121.1m)
Debt / EBITDA = 3.95 (Net Debt 12.11b / EBITDA 2.71b)
Debt / FCF = 8.30 (Debt 10.69b / FCF TTM 1.29b)
Total Stockholder Equity = -32.2m (last 4 quarters mean)
RoA = 4.78% (Net Income 836.3m, Total Assets 17.49b )
RoE = unknown (Net Income TTM 836.3m / Total Stockholder Equity -32.2m)
RoCE = 19.88% (Ebit 2.00b / (Equity -32.2m + L.T.Debt 10.08b))
RoIC = 16.79% (NOPAT 1.63b / Invested Capital 9.72b)
WACC = 4.81% (E(9.85b)/V(20.54b) * Re(8.82%)) + (D(10.69b)/V(20.54b) * Rd(1.37%) * (1-Tc(0.18)))
Shares Correlation 3-Years: -68.70 | Cagr: -1.68%
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 75.56% ; FCFE base≈1.28b ; Y1≈1.29b ; Y5≈1.37b
Fair Price DCF = 294.9 (DCF Value 21.09b / Shares Outstanding 71.5m; 5y FCF grow -0.16% → 3.0% )
EPS Correlation: 74.68 | EPS CAGR: 41.76% | SUE: 0.85 | # QB: 1
Revenue Correlation: 93.33 | Revenue CAGR: 5.08% | SUE: N/A | # QB: None
Additional Sources for DVA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle